ClinicalTrials.gg
RecruitingNCT06876714Updated Oct 2, 2026

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

A Phase 3 interventional study of Trastuzumab (Herceptin) and Pertuzumab in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Early Stage HER2+ Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology. Recruiting at 702 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 2, 2026Site recruiting status changed12 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,524
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Planned enrollment
16th of 366
1,524 · median 61
Started
2025
with 12 others
Phase 3
60 of 374
3 open now
Primary completion
2028-03
later than 67 of 85 live
Registered
352nd of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 16th largest by planned enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2025, is one of 60 in phase 3, reaches primary completion later than 67 of the 85 other live ones, and was the 352nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.

Read the detailed description

The primary and secondary objectives of the study:

PRIMARY OBJECTIVES:

I. To evaluate whether 6 months of combined neoadjuvant (neo)/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvant HER2 blockade, in patients with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.

II. To compare the Functional Assessment of Cancer Therapy-Breast (FACT-B) total score at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life)

SECONDARY OBJECTIVES:

I. Secondary objectives are to evaluate whether 6 months compared to 12 months results in differences for the following:

Ia. Grade 3 or higher adverse event (AE) rates; Ib. Overall survival (OS); Ic. Locoregional recurrence (LRR, both isolated LRR as first events, and LRR events simultaneous with distant metastasis [DM]) incidence; Id. RFS for key subgroups: baseline stage, hormone receptor (HR) status, neoadjuvant chemotherapy backbone, and dual versus single HER2 blockade in the adjuvant setting; Ie. Time to central nervous system (CNS) recurrence (both isolated CNS recurrence as first events, and CNS recurrence events simultaneous with distant metastasis and/or LRR).

II. To compare the FACT-B total score at 18 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) III. To compare side effect bother as measured by the Functional Assessment of Cancer Therapy General Population 5 (FACT GP5) item at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) IV. To compare specific patient-reported symptomatic adverse events (i.e. diarrhea, constipation, fatigue, and rash) as measured by the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life)

QUALITY OF LIFE EXPLORATORY OBJECTIVES:

I. To examine the different FACT-B subscales at all other evaluable time points.

II. To examine heterogeneity of treatment effects within subgroups defined by subcutaneous versus intravenous treatment delivery.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive trastuzumab intravenously (IV) or subcutaneously (SC) on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) or multigated acquisition (MUGA) as well as mammography, ultrasound, or magnetic resonance imaging (MRI) throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial.

ARM 2: Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial.

After completion of study treatment, patients are followed up every 6 months for 5 years after registration or until recurrence and then annually for a total of 10 years after registration.

03

Conditions studied

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Early Stage HER2+ Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients (females and males) with clinical stage T1c-T3 (or Tx) and nodal stage N0-N1 (except T3N1 tumors, which are not eligible)
  • Patients must have no residual invasive disease in the breast or lymph nodes after the completion of therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Patients with residual isolated tumor cells at surgery are considered node-positive and are not eligible
  • + by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Central pathology review is not required. In cases where there were multiple tumor sites in breast/nodes that had HER2 testing at diagnosis, at least one site must have been HER2+ AND the treating investigator must feel it is in the patient's best interest to be treated as having HER2+ breast cancer
  • Known hormone receptor status as defined by ASCO/CAP guidelines. Estrogen receptor (ER) and progesterone receptor (PR) of any values are allowed. Hormone receptor positive status can be determined by either known positive ER or known positive PR status; hormone receptor negative status must be determined by both known negative ER and known negative PR
  • If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts (including the requirement that at least one biopsied site on each side must have been HER2+)
  • Age ≥ 18 years
  • (ECOG) performance status 0-2
  • Patients must have received neoadjuvant chemotherapy in combination with trastuzumab with or without pertuzumab for a minimum of 12 weeks. All chemotherapy must have been completed preoperatively

    • Patient must complete a minimum of 12 weeks of coverage with trastuzumab and a maximum of 24 weeks in the combined neoadjuvant and adjuvant setting prior to trial registration. Trastuzumab may have been administered either weekly or once every 3 weeks (q3weeks). (For purposes of this eligibility criterion, a single dose of q3week trastuzumab would provide 3 weeks of coverage; a single dose of once a week (q1week) trastuzumab would provide 1 week of coverage. If a q3week dose of trastuzumab were administered and then the subsequent dose was delayed for any period of time, that would still count as 3 weeks of coverage.)
    • Administration of endocrine therapy for treatment of this breast cancer is allowed prior to trial registration. If a patient received prior breast cancer endocrine therapy (eg tamoxifen or aromatase inhibitor) for DCIS or preventive indication, and endocrine therapy is indicated for treatment of their current breast cancer, then prior endocrine therapy must have been stopped > 12 months prior to registration on this protocol
    • No use of anti-cancer agents at time of registration
  • Patient must register within 14 weeks of final surgery
  • Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows:

    • Breast surgery: Total mastectomy with grossly negative margins (in the opinion of the surgeon there is no disease grossly at the margins) or breast-conserving surgery with histologically negative margins (no ink on tumor, including DCIS) unless those margins are anterior at the skin or posterior at the chest wall and no additional margin re-excision can be performed
    • Lymph node surgery: Lymph node surgery must have been performed and can include sentinel lymph node , targeted axillary dissection, or axillary dissection, at the discretion of the breast surgeon
  • Adequate radiation: Patients who completed breast-conserving surgery (i.e. lumpectomy) must have received or plan to receive adjuvant radiation. If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible. Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation) are not eligible

    • Adjuvant radiation can be given on study, and in this case is encouraged to be given concurrently with adjuvant HER2-directed therapy, per investigator discretion
    • Targeting of the regional nodal basins will be at treating investigator discretion
  • Not pregnant and not nursing, because this study involves agents with known teratogenic potential. Therefore, for women of only, a negative serum or urine pregnancy test should be performed prior to receiving HER2-directed therapy according to local standard practice
  • Adequate hepatic, renal and bone marrow function to receive adjuvant HER2-directed therapy in the opinion of the treating investigator. There are no specific required laboratory values for eligibility
  • No stage IV () breast cancer
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • No history of any prior (ipsilateral [ipsi-] or contralateral) invasive breast cancer. Prior DCIS is allowed
  • No evidence of recurrent disease following preoperative therapy and surgery
  • Patients living with who are healthy and deemed by their medical team to have a low risk of AIDS-related illnesses are included in this trial. Patients with or virus who are healthy and deemed by their medical team to meet all other enrollment criteria are included in this trial.
  • Patients with inadequate cardiac function on most recent assessment of (LVEF) are not eligible for this trial. Inadequate cardiac function is defined as LVEF \< 50% on echocardiogram (echo) or multiple-gated acquisition (MUGA)
  • No history of grade 3 or 4 toxicity related to trastuzumab. If pertuzumab is planned to be given on trial, patient must also have no history of grade 3-4 toxicity related to pertuzumab
  • No contraindication to receipt of further HER2-directed therapy
  • No patients with severe, uncontrolled systemic disease that may interfere with planned trial therapy.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,524 participants (estimated)

Study arms

  • Active comparator
    Arm 1 (12-month adjuvant therapy)

    Patients receive trastuzumab IV or trastuzumab/hyaluronidase-oysk SC on day 1 of each cycle. Patients may also receive pertuzumab IV or hyaluronidase-zzxf/pertuzumab/trastuzumab SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial.

    Biological: Trastuzumab (Herceptin) · Biological: Pertuzumab · Procedure: Echocardiography · Procedure: Multigated Acquisition Scan · Procedure: Mammography · Procedure: Ultrasound · Procedure: Magnetic Resonance Imaging · Procedure: Biospecimen Collection · Other: Questionnaire Administration

  • Experimental
    Arm 2 (6-month adjuvant therapy)

    Patients receive trastuzumab IV or trastuzumab/hyaluronidase-oysk SC on day 1 of each cycle. Patients may also receive pertuzumab IV or hyaluronidase-zzxf/pertuzumab/trastuzumab SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial.

    Biological: Trastuzumab (Herceptin) · Biological: Pertuzumab · Procedure: Echocardiography · Procedure: Multigated Acquisition Scan · Procedure: Mammography · Procedure: Ultrasound · Procedure: Magnetic Resonance Imaging · Procedure: Biospecimen Collection · Other: Questionnaire Administration

Interventions

  • BiologicalTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV or SC

  • BiologicalPertuzumab

    Given IV or SC

  • ProcedureEchocardiography

    Undergo ECHO

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

  • ProcedureMammography

    Undergo mammography

  • ProcedureUltrasound

    Undergo ultrasound

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • ProcedureBiospecimen Collection

    Undergo blood and tissue sample collection

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival (RFS)

    The Kaplan-Meier method will be used to estimate the distribution of RFS times and a stratified log-rank test for non-inferiority will be used to assess whether RFS with 6 total months of human epidermal growth factor receptor 2 (HER2)-blockade is non-inferior to standard-of-care 12 total months of HER2-blockade in this patient population. Stratified Cox modeling will be used to estimate the hazard ratio and corresponding one-sided 95% confidence interval (CI).

    Time frame: From randomization to invasive local, regional or distant breast cancer recurrence, or death from any cause prior to a documented disease recurrence, assessed up to 10 years

  2. Functional Assessment of Cancer Therapy-Breast (FACT-B) total score (Quality of life)

    Will compare the FACT-B total score between patients randomized to receive 6 months versus 12 months of combined neoadjuvant/adjuvant HER2 blockade. All questionnaires will be scored according to published scoring algorithms, including recommendations for addressing missing items within a scale. An intention-to-treat (ITT) approach will be used for all analyses. All statistical tests will be 2-sided, and p-values \< 0.05 will be considered statistically significant. To evaluate the between-arm mean difference in scores, a repeated measures mixed model will be estimated based on FACT-B total scores at all time points.

    Time frame: At 12 months

Secondary outcomes

  1. Incidence of grade 3 or higher adverse events (AE)

    Will be according to the Common Terminology Criteria for Adverse Events version 5.0. The maximum grade of a specific AE experienced by a patient will be used. The proportion of patients who report a grade 3 or higher AE will be compared between the two treatment arms with a chi-square test. AEs (type and grade) for both arms will be summarized with the frequency and relative frequency

    Time frame: Baseline to 30 days after last dose of study treatment

  2. Locoregional recurrence (LRR)

    The cumulative incidence of LRR will be analyzed with Kaplan-Meier estimates (curve starting at 0 rather than 1) and compared with a stratified log rank test.

    Time frame: From randomization until invasive tumor recurs in the ipsilateral breast or chest wall, axillary, supraclavicular, or internal mammary nodes (if before or synchronous with a systemic recurrence), whichever comes first, assessed up to 10 years

  3. Overall survival

    Will be compared between the treatment arms with a stratified log rank test and a stratified Cox model will be used to generate the hazard ratio estimate (both a point estimate and 95% CI). The analyses will be done as ITT groups as well as per-protocol groups.

    Time frame: From randomization until death due to any cause, assessed up to 10 years

  4. RFS for key subgroups

    Forest plots will be generated for key prognostic variables (including the stratification variables) and subgroups of interest to determine whether the treatment effect appears homogeneous across the subgroups for the ITT population. Additional key subgroups of interest are neoadjuvant chemotherapy backbone and the type of adjuvant HER2-blockade the patient actually received (dual versus single). With respect to the latter analysis, the interest will be in whether there is an apparent difference in treatment effect among patients who received adjuvant pertuzumab versus those who did not.

    Time frame: From randomization to invasive local, regional or distant breast cancer recurrence, or death from any cause prior to a documented disease recurrence, assessed up to 10 years

  5. Time to central nervous system (CNS) recurrence

    Will assess both isolated CNS recurrence as first events, and CNS recurrence events simultaneous with distant metastasis and/or LRR.

    Time frame: up to 10 years

  6. FACT-B total score (Quality of life)

    Will compare the FACT-B total score between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. All questionnaires will be scored according to published scoring algorithms, including recommendations for addressing missing items within a scale. An ITT approach will be used for all analyses. All statistical tests will be 2-sided, and p-values \<0.05 will be considered statistically significant. To evaluate the between-arm mean difference in scores, a repeated measures mixed model will be estimated based on FACT-B total scores at all time points.

    Time frame: At 18 months

  7. Side effect bother (Quality of life)

    Will be assessed by Functional Assessment of Cancer Therapy General Population 5 between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. All questionnaires will be scored according to published scoring algorithms, including recommendations for addressing missing items within a scale. An ITT approach will be used for all analyses. All statistical tests will be 2-sided, and p-values \<0.05 will be considered statistically significant. To evaluate the between-arm mean difference in scores, a repeated measures mixed model will be estimated based on scores. Mean trajectories over time will be plotted by arm.

    Time frame: At 6 or 12 months

  8. Patient reported symptomatic AE (Quality of life)

    Will be measured by Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE). Will assess symptomatic AE using PRO-CTCAE measures for symptoms of interest, specifically diarrhea, constipation, fatigue, and rash. The proportion of patients with a maximum post-baseline score greater than 0 will be compared between arms using Fisher's exact test. For diarrhea, constipation, and fatigue, the proportion of patients with a maximum post-baseline score greater than or equal to 3 will be compared between arms using Fisher's exact test.

    Time frame: At 6 or 12 months

07

Study locations

604 of 702 sites recruiting

Showing the first 100 of 702 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 29 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Mar 13, 2028
CompletionEst.
Mar 13, 2037
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added. 24 sites changed recruiting status (16 now suspended, 8 now recruiting)
Show 24 sites
  • Saint Luke's Cancer Institute - Boise · Boise, United StatesRecruiting→Suspended
  • Saint Luke's Cancer Institute - Fruitland · Fruitland, United StatesRecruiting→Suspended
  • Saint Luke's Cancer Institute - Meridian · Meridian, United StatesRecruiting→Suspended
  • Saint Luke's Cancer Institute - Nampa · Nampa, United StatesRecruiting→Suspended
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute · Baltimore, United StatesRecruiting→Suspended
  • MedStar Good Samaritan Hospital · Baltimore, United StatesRecruiting→Suspended
  • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesSuspended→Recruiting
  • Trinity Health Muskegon Hospital · Muskegon, United StatesSuspended→Recruiting
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
  • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesSuspended→Recruiting
  • Upper Valley Medical Center · Troy, United StatesRecruiting→Suspended
  • Saint Charles Health System · Bend, United StatesRecruiting→Suspended
  • Providence Hood River Memorial Hospital · Hood River, United StatesRecruiting→Suspended
  • Providence Newberg Medical Center · Newberg, United StatesRecruiting→Suspended
  • Providence Willamette Falls Medical Center · Oregon City, United StatesRecruiting→Suspended
  • Swedish Cancer Institute-Edmonds · Edmonds, United StatesRecruiting→Suspended
  • Swedish Cancer Institute-Issaquah · Issaquah, United StatesRecruiting→Suspended
  • Skagit Regional Health Cancer Care Center · Mount Vernon, United StatesRecruiting→Suspended
  • Swedish Medical Center-First Hill · Seattle, United StatesRecruiting→Suspended
  • Aspirus Medford Hospital · Medford, United StatesRecruiting→Suspended
  • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
  • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
  • ProHealth Waukesha Memorial Hospital · Waukesha, United StatesSuspended→Recruiting
  • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
Show 12 added (12 United States)
  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler · Savannah, United States
  • Saint Alphonsus Cancer Care Center-Boise · Boise, United States
  • Saint Alphonsus Cancer Care Center-Caldwell · Caldwell, United States
  • Idaho Urologic Institute-Meridian · Meridian, United States
  • University of Iowa/Holden Comprehensive Cancer Center · Iowa City, United States
  • UMass Memorial Medical Center - University Campus · Worcester, United States
  • Saint Alphonsus Cancer Care Center-Ontario · Ontario, United States
  • Geisinger Medical Center · Danville, United States
  • WellSpan Medical Oncology and Hematology · Hanover, United States
  • Temple University Hospital · Philadelphia, United States
  • Saint Joseph's/Candler - Bluffton Campus · Bluffton, United States
  • South Carolina Cancer Specialists PC · Hilton Head Island, United States
Oct 2, 2026
Site contacts
Changed at 26 sites. See the sites
Show 26 sites
  • Saint Luke's Cancer Institute - Boise · Boise, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
  • Saint Luke's Cancer Institute - Fruitland · Fruitland, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
  • Saint Luke's Cancer Institute - Meridian · Meridian, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
  • Saint Luke's Cancer Institute - Nampa · Nampa, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute · Baltimore, United StatesContact removed •••7364Contact removed (no phone or email listed)
  • MedStar Good Samaritan Hospital · Baltimore, United StatesContact removed B•••@medstar.net · •••8151Contact removed (no phone or email listed)
  • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
  • Trinity Health Muskegon Hospital · Muskegon, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
  • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesContact added •••3000Contact added (no phone or email listed)
  • Upper Valley Medical Center · Troy, United StatesContact removed c•••@daytonncorp.org · •••2900Contact removed (no phone or email listed)
  • Saint Charles Health System · Bend, United StatesContact removed n•••@stcharleshealthcare.org · •••2909Contact removed (no phone or email listed)
  • Providence Hood River Memorial Hospital · Hood River, United StatesContact removed c•••@provdience.org · •••1979Contact removed (no phone or email listed)
  • Providence Newberg Medical Center · Newberg, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  • Providence Willamette Falls Medical Center · Oregon City, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
  • Swedish Cancer Institute-Edmonds · Edmonds, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
  • Swedish Cancer Institute-Issaquah · Issaquah, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
  • Skagit Regional Health Cancer Care Center · Mount Vernon, United StatesContact removed r•••@skagitvalleyhospital.org · •••2182Contact removed (no phone or email listed)
  • Swedish Medical Center-First Hill · Seattle, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
  • Aspirus Medford Hospital · Medford, United StatesContact removed B•••@aspirus.org · •••2353Contact removed (no phone or email listed)
  • ProHealth D N Greenwald Center · Mukwonago, United StatesContact added r•••@phci.orgContact added (no phone or email listed)
  • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesContact added •••7878Contact added (no phone or email listed)
  • ProHealth Waukesha Memorial Hospital · Waukesha, United StatesContact added •••7632Contact added (no phone or email listed)
  • UW Cancer Center at ProHealth Care · Waukesha, United StatesContact added C•••@phci.org · •••5539Contact added (no phone or email listed)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    12 sites added. 24 sites changed recruiting status (16 now suspended, 8 now recruiting)
    Show 24 sites
    • Saint Luke's Cancer Institute - Boise · Boise, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Fruitland · Fruitland, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Meridian · Meridian, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Nampa · Nampa, United StatesRecruiting→Suspended
    • MedStar Franklin Square Medical Center/Weinberg Cancer Institute · Baltimore, United StatesRecruiting→Suspended
    • MedStar Good Samaritan Hospital · Baltimore, United StatesRecruiting→Suspended
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesSuspended→Recruiting
    • Trinity Health Muskegon Hospital · Muskegon, United StatesSuspended→Recruiting
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
    • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesSuspended→Recruiting
    • Upper Valley Medical Center · Troy, United StatesRecruiting→Suspended
    • Saint Charles Health System · Bend, United StatesRecruiting→Suspended
    • Providence Hood River Memorial Hospital · Hood River, United StatesRecruiting→Suspended
    • Providence Newberg Medical Center · Newberg, United StatesRecruiting→Suspended
    • Providence Willamette Falls Medical Center · Oregon City, United StatesRecruiting→Suspended
    • Swedish Cancer Institute-Edmonds · Edmonds, United StatesRecruiting→Suspended
    • Swedish Cancer Institute-Issaquah · Issaquah, United StatesRecruiting→Suspended
    • Skagit Regional Health Cancer Care Center · Mount Vernon, United StatesRecruiting→Suspended
    • Swedish Medical Center-First Hill · Seattle, United StatesRecruiting→Suspended
    • Aspirus Medford Hospital · Medford, United StatesRecruiting→Suspended
    • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
    • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
    • ProHealth Waukesha Memorial Hospital · Waukesha, United StatesSuspended→Recruiting
    • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
    Show 12 added (12 United States)
    • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler · Savannah, United States
    • Saint Alphonsus Cancer Care Center-Boise · Boise, United States
    • Saint Alphonsus Cancer Care Center-Caldwell · Caldwell, United States
    • Idaho Urologic Institute-Meridian · Meridian, United States
    • University of Iowa/Holden Comprehensive Cancer Center · Iowa City, United States
    • UMass Memorial Medical Center - University Campus · Worcester, United States
    • Saint Alphonsus Cancer Care Center-Ontario · Ontario, United States
    • Geisinger Medical Center · Danville, United States
    • WellSpan Medical Oncology and Hematology · Hanover, United States
    • Temple University Hospital · Philadelphia, United States
    • Saint Joseph's/Candler - Bluffton Campus · Bluffton, United States
    • South Carolina Cancer Specialists PC · Hilton Head Island, United States
    Site contacts Changed at 26 sites. See the sites
    Show 26 sites
    • Saint Luke's Cancer Institute - Boise · Boise, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Fruitland · Fruitland, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Meridian · Meridian, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Nampa · Nampa, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • MedStar Franklin Square Medical Center/Weinberg Cancer Institute · Baltimore, United StatesContact removed •••7364Contact removed (no phone or email listed)
    • MedStar Good Samaritan Hospital · Baltimore, United StatesContact removed B•••@medstar.net · •••8151Contact removed (no phone or email listed)
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
    • Trinity Health Muskegon Hospital · Muskegon, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
    • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesContact added •••3000Contact added (no phone or email listed)
    • Upper Valley Medical Center · Troy, United StatesContact removed c•••@daytonncorp.org · •••2900Contact removed (no phone or email listed)
    • Saint Charles Health System · Bend, United StatesContact removed n•••@stcharleshealthcare.org · •••2909Contact removed (no phone or email listed)
    • Providence Hood River Memorial Hospital · Hood River, United StatesContact removed c•••@provdience.org · •••1979Contact removed (no phone or email listed)
    • Providence Newberg Medical Center · Newberg, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Swedish Cancer Institute-Edmonds · Edmonds, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
    • Swedish Cancer Institute-Issaquah · Issaquah, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
    • Skagit Regional Health Cancer Care Center · Mount Vernon, United StatesContact removed r•••@skagitvalleyhospital.org · •••2182Contact removed (no phone or email listed)
    • Swedish Medical Center-First Hill · Seattle, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
    • Aspirus Medford Hospital · Medford, United StatesContact removed B•••@aspirus.org · •••2353Contact removed (no phone or email listed)
    • ProHealth D N Greenwald Center · Mukwonago, United StatesContact added r•••@phci.orgContact added (no phone or email listed)
    • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesContact added •••7878Contact added (no phone or email listed)
    • ProHealth Waukesha Memorial Hospital · Waukesha, United StatesContact added •••7632Contact added (no phone or email listed)
    • UW Cancer Center at ProHealth Care · Waukesha, United StatesContact added C•••@phci.org · •••5539Contact added (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06876714
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Sep 17, 2025
Primary completion
Mar 13, 2028 (estimated)
Completion
Mar 13, 2037 (estimated)
Last update
Oct 2, 2026

Study contacts

Jack Beranek
Contact
breastprotocols@alliancenctn.org
773-702-9171
Adrienne Waks, MD
study chair · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Pertuzumab

Start the discussion